首页 | 本学科首页   官方微博 | 高级检索  
     


C-type natriuretic peptide in growth: A new paradigm
Affiliation:1. ImPACCT – Improving Palliative Aged and Chronic Care through Clinical Research and Translation, Faculty of Health, University of Technology Sydney, Sydney, Australia;2. Department of Medicine, Massachusetts General Hospital Cancer Center, Boston;3. Department of Medicine, Duke University School of Medicine, Durham, USA;4. Department of Pneumology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland;5. Helsinn Therapeutics (U.S.) Inc., Iselin, USA;6. Department of Surgery, Royal Infirmary, Edinburgh, UK
Abstract:C-type natriuretic peptide (CNP), acting through its receptor, natriuretic peptide receptor-B (NPR-B), plays a critical role in linear growth. Knockout mice for CNP and NPR-B are dwarfed, and transgenic mice overexpressing CNP are overgrown. CNP has a direct regulatory effect on growth plate chondrocytes, acting primarily to promote terminal differentiation and hypertrophy. In humans, homozygous NPR-B mutations are the cause of acromesomelic dysplasia, Maroteaux type (AMDM), a severe form of disproportionate dwarfism. A patient with AMDM and the NPR-B knockout mouse both have low insulin-like growth factor I (IGF-I) levels, suggesting an interaction between these regulatory systems. Heterozygous carriers of NPR-B mutations also have reduced stature, but no other abnormalities. Hence, heterozygous NPR-B mutations are another cause of “idiopathic” short stature. The CNP–NPR-B system has only recently been found to be an important regulator of human growth, and abnormalities in this system have clinical implications. Considerable work is needed to further understand this new paradigm of human growth regulation.
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号